The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $37.77, representing a -0.03% change from its previous close.

CRISPR Therapeutics (NasdaqGM:CRSP) witnessed a notable 25% gain over the past week, gaining traction amid an executive departure. The announcement of COO Julianne Bruno’s exit could have influenced ...

Learn about Brink Therapeutics as it raises $4 million to go beyond CRISPR with engineered recombinases in CAR T therapy.

BofA lowered the firm’s price target on Crispr Therapeutics (CRSP) to $80 from $86 and keeps a Buy rating on the shares. While Q1 earnings ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

Learn more about whether CRISPR Therapeutics AG or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ ...

Learn more about whether Amarin Corporation plc or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor ...

Summit Therapeutics (NASDAQ: SMMT), and Viking Therapeutics (NASDAQ: VKTX) as stocks worth buying now. (CRISPR Therapeutics): Despite creating Casgevy, the first CRISPR-based gene-editing medicine to ...

The Food and Drug Administration has approved the world’s first medicine based on CRISPR gene-editing technology, a ...

The global gene therapy market is projected to grow at a significant CAGR of 20% from 2024 to 2029. This growth is driven by ...

CRISPR Therapeutics may gain exclusive access to Bayer's protein engineering know-how for use in CRISPR products as well as Bayer's extensive expertise and knowledge in the three targeted disease ...

A recent publication in Genes & Diseases has delivered a compelling synthesis of the latest insights into the cellular ...